Sapheon hauls in $10M as it works toward FDA approval for a varicose vein device

North Carolina's Sapheon pulled down $10 million in financing to support the development of its VenaSeal system, a varicose vein-treating device going through the FDA's modular approval program. Under the agency's guidance, Sapheon has submitted the second round of data on VenaSeal and is in the midst of a 242-patient pivotal trial with hopes of getting the device approved by 2015. More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.